What's really going on with Lake Erie? OSU expert breaks it down June 10
The Ohio State University at Marion will host a community lecture on Lake Erie. The event is part of the Buckeye Talks on Tap series and will feature Christopher Winslow, Ph.D., the director of Ohio Sea Grant and Stone Laboratory.
The lecture, titled 'The State of Lake Erie: Nutrients and Harmful Algal Blooms,' is scheduled for 5:30 pm. Tuesday, June 10, at Bucci's Italian Scratch Kitchen.
Lake Erie plays a crucial role in Ohio's economy, transportation, recreation and tourism. It also serves as a drinking water source for millions of residents, according to an announcement. Winslow will discuss nutrient sources affecting Lake Erie, including agricultural nutrient losses and best management practices. He also will address strategies for achieving a 40% reduction in phosphorus, as well as gaps in information and research needs.
Winslow coordinates research, education and outreach efforts related to Lake Erie in collaboration with various state and federal agencies and universities. He holds a master's and doctorate from Bowling Green State University and a bachelor's degree from Ohio University. Before joining The Ohio State University, he served as an instructor at Bowling Green State University from 2002 to 2009 and as an assistant professor at Kutztown University of Pennsylvania from 2009 to 2011.
Buckeye Talks on Tap takes place the second Tuesday of each month at Bucci's Italian Scratch Kitchen, 320 W. Center St., Marion. Doors will open at 5 p.m., with the lecture starting at 5:30 p.m. An open discussion will follow at 6 p.m.
This story was created by Jane Imbody, jimbody@gannett.com, with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at cm.usatoday.com/ethical-conduct or share your thoughts at http://bit.ly/3RapUkA with our News Automation and AI team.
This article originally appeared on Marion Star: Lake Erie future at stake - join the conversation in Marion June 10
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
24 minutes ago
- Bloomberg
Ether Leads Crypto Selloff as US Attacks Nuclear Sites in Iran
Ether fell sharply while Bitcoin held steady after President Donald Trump said American bombers and missiles had struck Iran's three main nuclear sites. The second-ranked token fell as much as 7.7% on Sunday morning in Asia to about $2,200, its lowest intra-day level since May 9. Bitcoin briefly dipped below $101,000 but pared losses to trade relatively evenly in the aftermath of the attacks.
Yahoo
25 minutes ago
- Yahoo
Acadia Pharmaceuticals (ACAD) Conducts Inducement Awards to Attract and Retain Top Talent
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the 10 biotech stocks screaming a buy. On June 17, the company moved to attract and retain top talent by granting inducement awards to 41 employees. Under the 2024 Inducement Plan, the company will award the employees non-qualified stock options of 187,664 shares and 89.582 restricted stock units designed to attract and retain talent. A pharmacist in a pharmacy preparing a prescription medication for a patient suffering from Fibromyalgia. The move to offer inducement awards is part of Acadia Pharmaceuticals' push to secure top-skilled professionals essential for its neuroscience projects. It expects the awards to ensure employees are incentivized to contribute to the long-term objectives expected to lead to sustained growth and innovation. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharma company dedicated to advancing treatments for central nervous system disorders and rare diseases. Its key products include NUPLAZID, approved for Parkinson's disease psychosis, and DAYBUE. While we acknowledge the potential of ACAD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
25 minutes ago
- Yahoo
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been with Ionis since 1995 and played a pivotal role in bringing six medicines to regulatory approval, including the company's first independently commercialized drug, TRYNGOLZA. A biotechnologist pouring liquid into a test tube and analyzing its components in a lab. Dr. Kordasiewicz, who joined Ionis in 2011, brings over 20 years of experience in R&D, particularly in neurology. She leads the company's neurology program, covering treatments for conditions such as Alzheimer's disease, Angelman syndrome, and Alexander disease. Her work has also contributed to key partnered programs with Biogen, including the development of QALSODY® and IONIS-MAPTRx. As Dr. Geary transitions out of his role, he will continue as a strategic consultant through 2026 to ensure continuity. Ionis leadership praised both Geary's legacy and Kordasiewicz's appointment as a pivotal step in driving the company's commitment to developing transformational therapies for patients with serious diseases. Ionis Pharmaceuticals, Inc. is a U.S.-based commercial-stage biotech company specializing in RNA-targeted therapies. Its approved products include TRYNGOLZA for FCS, WAINUA, and TEGSEDI for ATTRv-PN, SPINRAZA for spinal muscular atrophy, QALSODY for ALS, and WAYLIVRA for rare lipid disorders. The company has a robust pipeline, including late-stage programs like Olezarsen (for hypertriglyceridemia), Donidalorsen (for hereditary angioedema), and Zilganerse (for Alexander disease), along with several mid-stage treatments for neurological and metabolic conditions. Ionis also collaborates with leading pharma firms, including Biogen, GSK, AstraZeneca, Novartis, Roche, and Metagenomi, expanding its reach in developing transformative RNA therapies. While we acknowledge the potential of IONS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None.
